OpenURL Connection Search

Select item for more details and to access through your institution.

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Published in:
Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-22139-7
By:
- Baca, Sylvan C.;
- Takeda, David Y.;
- Seo, Ji-Heui;
- Hwang, Justin;
- Ku, Sheng Yu;
- Arafeh, Rand;
- Arnoff, Taylor;
- Agarwal, Supreet;
- Bell, Connor;
- O'Connor, Edward;
- Qiu, Xintao;
- Alaiwi, Sarah Abou;
- Corona, Rosario I.;
- Fonseca, Marcos A. S.;
- Giambartolomei, Claudia;
- Cejas, Paloma;
- Lim, Klothilda;
- He, Monica;
- Sheahan, Anjali;
- Nassar, Amin
Publication type:
Article
Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.
Published in:
Scientific Reports, 2017, v. 7, n. 1, p. 1, doi. 10.1038/s41598-017-16558-0
By:
- Arafeh, Rand;
- Flores, Karen;
- Keren-Paz, Alona;
- Maik-Rachline, Galia;
- Gutkind, Naomi;
- Rosenberg, Steven;
- Seger, Rony;
- Samuels, Yardena
Publication type:
Article
CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.
Published in:
eLife, 2022, p. 1, doi. 10.7554/eLife.73223
By:
- Hwang, Justin H.;
- Arafeh, Rand;
- Ji-Heui Seo;
- Baca, Sylvan C.;
- Ludwig, Megan;
- Arnoff, Taylor E.;
- Sawyer, Lydia;
- Richter, Camden;
- Tape, Sydney;
- Bergom, Hannah E.;
- McSweeney, Sean;
- Rennhack, Jonathan P.;
- Klingenberg, Sarah A.;
- Cheung, Alexander T. M.;
- Kwon, Jason;
- So, Jonathan;
- Kregel, Steven;
- Van Allen, Eliezer M.;
- Drake, Justin M.;
- Freedman, Matthew L.
Publication type:
Article
Harnessing synthetic lethality to predict the response to cancer treatment.
Published in:
Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-04647-1
By:
- Joo Sang Lee;
- Das, Avinash;
- Jerby-Arnon, Livnat;
- Arafeh, Rand;
- Auslander, Noam;
- Davidson, Matthew;
- McGarry, Lynn;
- James, Daniel;
- Amzallag, Arnaud;
- Seung Gu Park;
- Kuoyuan Cheng;
- Robinson, Welles;
- Atias, Dikla;
- Stossel, Chani;
- Buzhor, Ella;
- Stein, Gidi;
- Waterfall, Joshua J.;
- Meltzer, Paul S.;
- Golan, Talia;
- Hannenhalli, Sridhar
Publication type:
Article
Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.
Published in:
Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-018-37931-7
By:
- Arafeh, Rand;
- Flores, Karen;
- Keren-Paz, Alona;
- Maik-Rachline, Galia;
- Gutkind, Naomi;
- Rosenberg, Steven;
- Seger, Rony;
- Samuels, Yardena
Publication type:
Article
A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma.
Published in:
Pigment Cell & Melanoma Research, 2020, v. 33, n. 2, p. 334, doi. 10.1111/pcmr.12825
By:
- Nagler, Adi;
- Vredevoogd, David W.;
- Alon, Michal;
- Cheng, Phil F.;
- Trabish, Sophie;
- Kalaora, Shelly;
- Arafeh, Rand;
- Goldin, Victoria;
- Levesque, Mitchell P.;
- Peeper, Daniel S.;
- Samuels, Yardena
Publication type:
Article

Found: 6

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.

Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.

CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.

Harnessing synthetic lethality to predict the response to cancer treatment.

Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.

A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma.